Athenex to acquire Kuur to develop cell therapies

By The Science Advisory Board staff writers

May 5, 2021 -- Athenex plans to acquire Kurr Therapeutics, including its allogeneic chimeric antigen receptor-natural killer T (CAR-NKT) cell platform, to expand its cell therapy development.

Kurr's platform aids in the development immunotherapies‌ ‌for‌ ‌the‌ ‌treatment‌ ‌of‌ ‌solid‌ ‌and‌ ‌hematological‌ ‌malignancies.‌ ‌

Athenex will pay $70 million upfront to Kurr shareholders, as well as some employees and directors. Additionally,‌ ‌they‌ ‌are‌ ‌eligible‌ ‌to‌ ‌receive‌ ‌up‌ ‌to‌ ‌$115‌ ‌million‌ ‌in‌ ‌milestone‌ ‌payments. Milestone payments of cash, common stock, or combination would be made at Athenex's sole discretion.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.